Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$19.54 ▼ -0.29
(-1.46%)
MKT CAP: $953.0M • VOL: 166.4K
52W L $15 52W H $29
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$16
MEDIAN
$22
MEAN
$22
HIGH
$27
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ODTX TAPE
ODTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $23.64 | $22.47 | 2025-02-14 | $17.78 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $24.62 | $23.06 | 2025-02-06 | $18.37 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $22.28 | $21.49 | 2025-01-29 | $18.76 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $19.93 | — | 2025-01-17 | $19.15 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $17.20 | $18.56 | 2025-01-09 | $17.39 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $23.25 | $20.32 | 2024-12-18 | $17.00 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $18.95 | $19.74 | 2024-12-04 | $18.17 | -4.3% | 48% | C |